Baxter Bros Inc. Has $3.95 Million Holdings in Eli Lilly and Company $LLY

Baxter Bros Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 319.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,176 shares of the company’s stock after buying an additional 3,942 shares during the period. Baxter Bros Inc.’s holdings in Eli Lilly and Company were worth $3,949,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in LLY. Roffman Miller Associates Inc. PA bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $12,606,000. Elevation Wealth Partners LLC boosted its stake in Eli Lilly and Company by 8.2% during the third quarter. Elevation Wealth Partners LLC now owns 608 shares of the company’s stock worth $464,000 after acquiring an additional 46 shares in the last quarter. Security Financial Services INC. grew its holdings in Eli Lilly and Company by 1.7% in the third quarter. Security Financial Services INC. now owns 1,230 shares of the company’s stock worth $938,000 after purchasing an additional 20 shares during the period. Berger Financial Group Inc increased its stake in Eli Lilly and Company by 0.8% in the third quarter. Berger Financial Group Inc now owns 6,763 shares of the company’s stock valued at $5,160,000 after purchasing an additional 51 shares in the last quarter. Finally, BigSur Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 6.4% during the third quarter. BigSur Wealth Management LLC now owns 2,340 shares of the company’s stock valued at $1,785,000 after purchasing an additional 140 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, December 16th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. UBS Group reaffirmed a “neutral” rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Thursday, December 4th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,070.80 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company’s 50 day moving average price is $971.08 and its two-hundred day moving average price is $835.68. The stock has a market cap of $1.01 trillion, a P/E ratio of 52.39, a P/E/G ratio of 1.09 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks raised quarterly and full‑year EPS estimates for LLY, reflecting stronger-than-expected GLP-1 and franchise momentum which supports earnings upside. Zacks raises LLY estimates
• Positive Sentiment: Forbes outlines three possible catalysts that could trigger an LLY rally (pipeline readouts, successful oral GLP‑1 launch execution and M&A/partnerships), providing a roadmap for upside if Lilly executes. 3 Catalysts That Can Start An Eli Lilly Stock Rally
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) and positive Phase‑3/clinical data updates (breast cancer, EMBER‑3 imlunestrant results) keep long‑term conviction intact for growth beyond obesity drugs. Jim Cramer on Lilly
• Positive Sentiment: Broker support remains: Bank of America and others maintain Buy/overweight views and some firms have raised price targets based on eventual realization of obesity‑drug earnings. This provides analyst backing for potential rebounds. BofA maintains Buy on Eli Lilly
• Neutral Sentiment: Sector rotation into healthcare/XLV increases passive demand for LLY (it’s a large ETF holding), supporting structural investor interest even amid short‑term volatility. Sector Rotation: 2 Smart Money Moves for 2026
• Neutral Sentiment: Deal speculation (reported meetings with Abivax/French officials) and ongoing partnership chatter could be upside optionality but are early-stage and uncertain. Abivax soars on Lilly meeting report
• Negative Sentiment: Major near-term headwind: the FDA approved Novo Nordisk’s oral Wegovy pill — the first daily oral obesity drug — giving Novo a first‑mover advantage that could pressure Lilly’s orforglipron launch timing/market share and is driving the stock pullback. Novo Nordisk weight-loss drug wins US approval as a daily pill
• Negative Sentiment: Market reaction and commentary: multiple outlets report LLY shares falling as investors re‑price competitive risk and potential slower or lower peak sales for Lilly’s oral GLP‑1; near‑term investor focus will be on comparative efficacy, launch execution, and pricing dynamics. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.